Gilead price target raised to $102 from $94 at BMO Capital
The Fly

Gilead price target raised to $102 from $94 at BMO Capital

BMO Capital raised the firm’s price target on Gilead (GILD) to $102 from $94 and keeps an Outperform rating on the shares. The firm cites a “consistent steady performance” from Gilead this quarter, which continues to show the reliable strength in its HIV business, the analyst tells investors in a research note. This is encouraging ahead of the company’s U.S. filing of lenacapavir for PrEP, BMO added.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App